In conclusion, our results suggest that GPX4 inhibits ferroptosis and promotes endometrial carcinoma progression through ELK1 transcriptional activation, and ELK1 / GPX4 axis is expected to become a new direction for the treatment of EC. Here, ELK1 is linked to endometrial carcinoma.